Open-Label Study Assessing Relative and Absolute Bioavailability of Oral Camizestrant Formulations and Food Effects in Healthy Postmenopausal Women

This study involving John McDermott (VP of Scientific Consulting) and Chris Roe (Principal Research Fellow, Scientific Consulting) at Quotient Sciences, investigates the impact of manufacturing changes during pivotal Phase 3 studies. 

This open-label, randomized crossover study of 32 postmenopausal healthy volunteers determined the relative bioavailability of a tablet used in early clinical studies.

The study was conducted by Quotient Sciences (Quotient) on behalf of AstraZeneca at a research site in Nottingham, UK